Diagnostic testing, information and services provider, Quest Diagnostics, is selling $1.25 billion worth of notes in a multi-tranche offering. Morgan Stanley, Goldman Sachs, RBS Securities, JP Morgan Securities and Wells Fargo Securities are the joint bookrunning managers for the issue. The issue includes $200 million three-year floating-rate notes, $300 million three-year fixed-rate piece, a $550 million 10-year tranche and $200 million of 30-year notes. The company intends to partly use the proceeds to fund a portion of its acquisition of Athena Diagnostics.
Click here for the release from Quest Diagnostics.